REAL-WORLD (RW) CLINICAL OUTCOMES AND CORRELATION OF RECURRENCE FREE SURVIVAL (RFS) AND DISTANT METASTASIS SURVIVAL (DMFS) TO OVERALL SURVIVAL (OS) IN RESECTED STAGE III-IV CUTANEOUS MELANOMA
Author(s)
Wolfram Samlowski, MD1, Yuexin Tang, PhD2, Wenyang Mao, PhD3, Lang Xu, MS4, Ahong Huang, MS5, Ke Meng, PhD6, Dmitri Grebennik, MD7, Sameer Ghate, PhD8.
1University of Nevada, Las Vegas, NV, USA, 2Merck & Co Inc, Rahway, NJ, USA, 3Tigermed BDM, Newton Upper Falls, MA, USA, 4Tigermed-BDM, Boston, MA, USA, 5Tigermed-BDM, Allen, TX, USA, 6Merck, Rahway, NJ, USA, 7Merck & Co. Inc., North Wales, PA, USA, 8Merck & Co. Inc, Rahway, NJ, USA.
1University of Nevada, Las Vegas, NV, USA, 2Merck & Co Inc, Rahway, NJ, USA, 3Tigermed BDM, Newton Upper Falls, MA, USA, 4Tigermed-BDM, Boston, MA, USA, 5Tigermed-BDM, Allen, TX, USA, 6Merck, Rahway, NJ, USA, 7Merck & Co. Inc., North Wales, PA, USA, 8Merck & Co. Inc, Rahway, NJ, USA.
OBJECTIVES: Patients with stage III-IV melanoma with no evidence of disease (NED) after surgery remain at substantial risk for disease recurrence. Treatment with anti-PD1 adjuvant therapies (AT) have demonstrated efficacy in reducing the risk of recurrence in clinical studies. This study evaluated clinical outcomes and associations of rwRFS and rwDMFS with rwOS in clinical practice.
METHODS: Adult patients diagnosed with stage III-IV NED cutaneous melanoma during 2018-2025 were identified from the US Oncology Network. Eligible patients underwent surgery and either received anti-PD1 AT (pembrolizumab or nivolumab within 11 weeks post-resection) or no-AT. Kaplan-Meier methods were used to estimate rwRFS, rwDMFS, and rwOS. Kendall τ coefficients assessed correlations of rwRFS/rwOS and rwDMFS/rwOS.
RESULTS: Among patients treated with anti-PD1 AT, 36-month rwRFS rates were 85.1% for IIIA (n=135), 73.0% for IIIB (n=100), and 69.3% for IIIC-IV (n=207) patients, respectively. 36-month rwDMFS rates were 88.0%, 78.7%, and 74.0% for IIIA, IIIB, and IIIC-IV patients. 36-month rwOS rates were 93.0%, 85.9%, and 83.7% for IIIA, IIIB, and IIIC-IV patients. At 36 months, rwRFS ranged from 74.6% to 34.3%, rwDMFS ranged from 75.3% to 42.2%, and rwOS ranged from 85.0% to 55.8% across stage IIIA, IIIB, and IIIC-IV patients receiving no-AT. In anti-PD1 AT patients, Kendall τ coefficients of rwRFS/rwOS were 0.92 (95% CI: 0.87-0.98), 0,84 (0.74, 0.94), and 0.80 (0.73, 0.87) in stage IIIA, IIIB, and IIIC-IV patients; for rwDMFS/rwOS, they were 0.96 (0.94-0.99), 0.91 (0.83, 0.99), and 0.87 (0.81, 0.93), respectively. In no-AT patients, Kendall τ coefficients ranged 0.85-0.77 for rwRFS/rwOS and 0.90-0.85 for rwDMFS/rwOS across substages.
CONCLUSIONS: Anti-PD1 AT was associated with numerically improved rwRFS, rwDMFS, and rwOS across substages, compared with no-AT. Correlations of rwRFS and rwDMFS with rwOS support their relevance as early indicators of long-term benefit across substages in AT-treated resected stage III-IV melanoma patients.
METHODS: Adult patients diagnosed with stage III-IV NED cutaneous melanoma during 2018-2025 were identified from the US Oncology Network. Eligible patients underwent surgery and either received anti-PD1 AT (pembrolizumab or nivolumab within 11 weeks post-resection) or no-AT. Kaplan-Meier methods were used to estimate rwRFS, rwDMFS, and rwOS. Kendall τ coefficients assessed correlations of rwRFS/rwOS and rwDMFS/rwOS.
RESULTS: Among patients treated with anti-PD1 AT, 36-month rwRFS rates were 85.1% for IIIA (n=135), 73.0% for IIIB (n=100), and 69.3% for IIIC-IV (n=207) patients, respectively. 36-month rwDMFS rates were 88.0%, 78.7%, and 74.0% for IIIA, IIIB, and IIIC-IV patients. 36-month rwOS rates were 93.0%, 85.9%, and 83.7% for IIIA, IIIB, and IIIC-IV patients. At 36 months, rwRFS ranged from 74.6% to 34.3%, rwDMFS ranged from 75.3% to 42.2%, and rwOS ranged from 85.0% to 55.8% across stage IIIA, IIIB, and IIIC-IV patients receiving no-AT. In anti-PD1 AT patients, Kendall τ coefficients of rwRFS/rwOS were 0.92 (95% CI: 0.87-0.98), 0,84 (0.74, 0.94), and 0.80 (0.73, 0.87) in stage IIIA, IIIB, and IIIC-IV patients; for rwDMFS/rwOS, they were 0.96 (0.94-0.99), 0.91 (0.83, 0.99), and 0.87 (0.81, 0.93), respectively. In no-AT patients, Kendall τ coefficients ranged 0.85-0.77 for rwRFS/rwOS and 0.90-0.85 for rwDMFS/rwOS across substages.
CONCLUSIONS: Anti-PD1 AT was associated with numerically improved rwRFS, rwDMFS, and rwOS across substages, compared with no-AT. Correlations of rwRFS and rwDMFS with rwOS support their relevance as early indicators of long-term benefit across substages in AT-treated resected stage III-IV melanoma patients.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
CO215
Topic
Clinical Outcomes
Topic Subcategory
Relating Intermediate to Long-term Outcomes
Disease
Oncology